Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT06848868
Recruiting
Ambulatory Flexible URS for UTUC Surveillance
Phase 1 · Hong Kong · 2 sites
Registry update: 15 Sept 2025
NCT06982794
Recruiting
A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
Not applicable · Italy · 1 site
Registry update: 21 May 2025
NCT07038928
Recruiting
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
Not applicable · Russia · 16 sites
Registry update: 14 Sept 2026
NCT06995677
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2 · Australia, Spain, France, Italy, United States · 51 sites
Registry update: 27 Oct 2026
NCT06896162
Recruiting
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Not applicable · United States · 1 site
Registry update: 14 Jul 2026
NCT06963346
Recruiting
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Phase 1 · United States · 1 site
Registry update: 30 Oct 2026
NCT06862219
Recruiting
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Phase 4 · India · 15 sites
Registry update: 21 Aug 2026
NCT07334314
Recruiting
Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs
Not applicable · France · 2 sites
Registry update: 12 Jan 2026
NCT06818136
Recruiting
Bladder EpiCheck European Haematuria Study
Not applicable · United Kingdom · 5 sites
Registry update: 22 Jan 2026
NCT07581496
Recruiting
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
Not applicable · Switzerland · 2 sites
Registry update: 18 May 2026
NCT06995898
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Not applicable · United States · 46 sites
Registry update: 6 Nov 2026
NCT06668493
Recruiting
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Phase 1/2 · Spain, France, Netherlands, United States · 12 sites
Registry update: 15 Sept 2026
NCT06686381
Recruiting
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
Phase 2 · Lebanon · 1 site
Registry update: 29 Oct 2026
NCT06971614
Recruiting
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Phase 2 · United States · 9 sites
Registry update: 18 Aug 2026
NCT06770582
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Phase 2 · Canada, United States · 147 sites
Registry update: 9 Nov 2026
NCT06999187
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · United States · 10 sites
Registry update: 7 Jan 2026
NCT06781879
Recruiting
Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer
Phase 4 · Denmark, Iceland, Norway, Sweden · 8 sites
Registry update: 3 Oct 2025
NCT07111364
Recruiting
Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study
Not applicable · China · 1 site
Registry update: 17 Aug 2025
2022-502221-18-00
Recruiting
Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer
Phase 4 · Denmark, Iceland, Norway, Sweden · 9 sites
Registry update: 13 Apr 2026
NCT04369560
Recruiting
Virtual Histology of the Bladder Wall for Bladder Cancer Staging
Early phase 1 · United States · 1 site
Registry update: 17 Dec 2025

Ordered by registry start date. Freshness and sponsorship never change the order.